Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de documento
Ano de publicação
Intervalo de ano de publicação
1.
Lupus ; 33(2): 137-144, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38164913

RESUMO

OBJECTIVE: Systemic lupus erythematosus (SLE) disproportionately affects patients from racial and ethnic minority groups. Medication adherence is lower among these patient populations, and nonadherence is associated with worse health outcomes. We aimed to identify factors that enable adherence to immunosuppressive medications among patients with SLE from racial and ethnic minority groups. METHODS: Using a qualitative descriptive study design, we conducted in-depth interviews with purposefully selected (1) patients with SLE from racial and ethnic minority groups who were taking immunosuppressants and (2) lupus providers and staff. We focused on adherence facilitators, asking patients to describe approaches supporting adherence and for overcoming common adherence challenges and providers and staff to describe actions they can take to foster patient adherence. We used applied thematic analysis and categorized themes using the Capability, Opportunity, Motivation, Behavior (COM-B) model. RESULTS: We interviewed 12 patients (4 adherent and 8 nonadherent based on medication possession ratio) and 12 providers and staff. Although each patient described a unique set of facilitators, patients most often described social support, physical well-being, reminders, and ability to acquire medications as facilitators. Providers also commonly mentioned reminders and easy medication access as facilitators as well as patient education/communication and empowerment. CONCLUSION: Using an established behavioral change model, we categorized a breadth of adherence facilitators within each domain of the COM-B model while highlighting patients' individual approaches. Our findings suggest that an optimal adherence intervention may require a multi-modal and individually tailored approach including components from each behavioral domain-ensuring medication access (Capability) and utilizing reminders and social support (Opportunity), while coupled with internal motivation through improved communication and empowerment (Motivation).


Assuntos
Lúpus Eritematoso Sistêmico , Reumatologia , Humanos , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Etnicidade , Grupos Minoritários , Pesquisa Qualitativa , Adesão à Medicação
2.
Neurocase ; 24(1): 16-30, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29308699

RESUMO

Posterior cortical atrophy (PCA) is a rare neurodegenerative syndrome characterized by initial predominant visuoperceptual deficits followed by a progressive decline in other cognitive functions. This syndrome has not been as thoroughly described as other dementias, particularly from a neuropsychological evolution perspective with only a few studies describing the evolution of its cognitive progression. In this investigation we review the literature on this rare condition and we perform a 7-year neuropsychological and neuroradiological follow-up of a 64-year-old man with PCA. The subject's deficits initially appeared in his visuoperceptual skills with later affectation appearing in language and other cognitive functions, this being coherent with the patient's parieto-temporal atrophy evolution.


Assuntos
Encefalopatias/complicações , Córtex Cerebral/diagnóstico por imagem , Transtornos Cognitivos/etiologia , Transtornos da Percepção/etiologia , Atrofia/complicações , Atrofia/diagnóstico por imagem , Encefalopatias/genética , Transtornos Cognitivos/diagnóstico por imagem , Transtornos Cognitivos/genética , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Neuroimagem , Testes Neuropsicológicos , Transtornos da Percepção/genética , Percepção Visual/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA